Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
22. November 2024 08:00 ET
|
Aptose Biosciences, Inc.
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
20. November 2024 07:30 ET
|
Aptose Biosciences, Inc.
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
Aptose Reports Results for the Third Quarter 2024
08. November 2024 16:01 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Announces Results from Special Meeting of Shareholders
05. September 2024 16:15 ET
|
Aptose Biosciences, Inc.
Aptose Announces Results from Special Meeting of Shareholders
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
30. August 2024 16:30 ET
|
Aptose Biosciences, Inc.
Aptose Receives $10 Million Through a Facility Agreement with Hanmi;
Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
Aptose Announces Adjournment of its Special Meeting of Shareholders
15. August 2024 16:30 ET
|
Aptose Biosciences, Inc.
Aptose Announces Adjournment of its Special Meeting of Shareholders
Aptose Reports Results for the Second Quarter 2024
08. August 2024 17:06 ET
|
Aptose Biosciences, Inc.
Aptose Reports Results for the Second Quarter 2024
Aptose Announces Receipt of Deficiency Notice from Nasdaq
19. Juli 2024 17:00 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Announces Results from Annual and Special Meeting of Shareholders
18. Juni 2024 17:30 ET
|
Aptose Biosciences, Inc.
Aptose Announces Results from Annual and Special Meeting of Shareholders
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
14. Juni 2024 07:30 ET
|
Aptose Biosciences, Inc.
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress